Myriad Genetics, Inc.

Healthcare · Diagnostics & Research · United States

Last price 6.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 637.98M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a...